Abstract:Objective to investigate the clinical effect and safety of percutaneous transhepatic portal vein stent placement(PTPVS) combined with transcatheter arterial chemoembolization(TACE) for the treatment of hepatocellular carcinoma(HCC) complicated by tumor thrombus in portal vein,and to discuss the possible factors affecting the prognosis.Methods According to the inclusion criteria and exclusion criteria,62 patients with clinically-confirmed HCC associated with portal vein tumor thrombus,who were encountered during the period from January 2009 to October 2010 in authors' hospital,were enrolled in this prospective two-arm nonrandomized trail.These patients were randomly divided into study group(n = 32) and control group(n = 30).Simple TACE(THP 40 mg/m2,Oxaliplatin 135 mg/m2,mitomycin C 6 mg/m2,lipiodol 5-20 ml) was used in patients of control group,while PTPVS with subsequent TACE was employed in patients of study group.PTPVS failed in two patients of study group.The overall survival time and the safety were used as the evaluation indexes.All patients were followed up.The procedure-related complications occurred after PTPVS were recorded.A data base on clinical information and follow-up outcome of all patients was set up and SPSS13.0 was used for statistical analysis.Median survival time and survival curve of the patients were analyzed by Kaplan-Meier method.A log-rank analysis was performed to identify group differences.Cox's proportional hazards model was used to analyze the variables affecting the patients' prognosis.Results The median overall survival time of the study group was 6.5 months,while the median overall survival time of the control group was 4.5 months(hazard ratio in the study group: 0.57,95%,confidence interval: 0.328-0.992,P = 0.037).Significant difference in the median overall survival time existed between the two groups.The cumulative survival rates at 3,6,12 and 18 months in the study group were 70%,56.7%,10% and 3.3%,respectively.In the study group,no procedure-related complications occurred within 1 week after the operation.The long-term complications in the study group included hepatic encephalopathy(n = 2,6.6%),upper gastrointestinal hemorrhage such as hematemesis and melen(n = 3,10%) and hepatorenal syndrome(n = 1,3.3%).Conclusion For the treatment of patients with HCC complicated by partial obstruction of the main trunk or the rst-order branch of the portal vein due to tumor thrombus,PTPVS combined with TACE is safe and effective.this combination therapy can improve The median survival time of patients receiving this combination therapy is about two months longer than that of patients receiving TACE alone.

Combined Postoperative Adjuvant Transarterial Chemoembolization and Portal Vein Chemotherapy to Treat Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis: a Meta-Analysis

Combined Three Intervened Treatment of TACE,PEI And PVC in Advanced Liver Cancer

Efficacy of Postoperative Transarterial Chemoembolization and Portal Vein Chemotherapy for Patients with Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis - A Randomized Study

Postoperative Adjuvant Chemo (embolization) Therapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.

Efficacy of Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Thrombosis: a Meta-Analysis.

Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: a Meta-Analysis

Transartenal chemoembolization and portal vein chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis

Effects of Transcatheter Arterial Chemoembolization in Combination with Portal Vein Chemotherapy on Survival of Patients after Resection of Hepatocellular Carcinoma

Transarterial Chemoembolization for Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombosis.

Evaluation of the Therapeutic Effect of Hepatic Arterial Chemoembolization Combined with Portal Chemoembolization for Advanced Hepatic Carcinomas

Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis

Therapeutic effect of postoperative transarterial chemoembolization and portal vein chemotherapy on primary liver cancer with portal vein tumor thrombus

Portal Vein Stent Placement Combined with TACE for the Treatment of Hepatocellular Carcinoma Associated with Tumor Thrombus in Portal Vein

TACE with Portal Vein Radioactive Seeds for HCC with Portal Vein Tumor Thrombus: a Meta-Analysis

The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus.

Does Postoperative Adjuvant Transarterial Chemoembolization Benefit for All Patients with Hepatocellular Carcinoma Combined with Microvascular Invasion: a Meta-Analysis

Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study

Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus

Transcatheter Arterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Resection Plus Post-operative Adjuvant Transcatheter Arterial Chemoembolization (TACE) Compared with Resection Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Postoperative Adjuvant Transarterial Chemoembolization Improves Outcomes of Hepatocellular Carcinoma Associated with Hepatic Vein Invasion: A Propensity Score Matching Analysis